Skip to main content

Table 2 Off-label use of tocilizumab in pediatric patients with JIA-associated uveitis

From: Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Authors, year (ref.) Sex Age at onset, years Age at TCZ, years Previous therapy Dose of TCZ Efficacy of TCZ Duration of TCZ Adverse effect of TCZ
Tsang et al., 2014 [60] M 3 12 GC, MTX, ADA, RTX 8 mg/kg/2–4 weeks Quiescence of uveitis 20 weeks Neutropenia when infused every 2 weeks
Tappeiner et al., 2016 [58] F:M 14:3   15.3 ± 6.9 GC, MTX, ≥1 TNF-α inhibitor   Inactive in 10, persisted in 7 5.7 months No
Calvo-Rio et al., 2017 [57] F:M 21:4   18.5 ± 8.3 (8–38) GC, MTX, IFX, ETN, ADA, GLM, ABA, ANK, RTX 8 mg/kg/2, 4, 8 weeks Inactive in 19 cases 5.5–24 months Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), Viral conjunctivitis and bullous impetigo (1)
162 mg/week SC
Quesada-Masachs et al., 2017 [62] F 1.9 14 MTX, leflunomide, ADA 8 mg/kg/month switching to 162 mg/week SC Ocular flare after 6 months 6 months No
  1. TCZ tocilizumab, GC glucocorticoids, MTX methotrexate, ADA adalimumab, RTX rituximab, TNF tumor necrosis factor, IFX infliximab, ETN etanercept, GLM golimumab, ABA abatacept, ANK anakinra